Zydus Pharmaceuticals Inc
- All
- News
-
Zydus Cadila's US Firm Gets US Approval To Market Roflumilast Tablets
Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of
-
Cadila Settles Patent Litigation Related To Anti-Seizure Drug
Drug firm Cadila Healthcare today said it has settled all outstanding patent litigation related to Qudexy XR (topiramate) extended-release capsules with US-based Upsher-Smith Laboratories, Inc.
-
Zydus To Sell Ulcerative Colitis Treatment Generic Drug In US Market
Drug firm Cadila Healthcare's US arm Zydus Pharmaceuticals (USA) Inc will start selling a generic version of Asacol HD, used for treatment of ulcerative colitis, in the American market from August 1, 2016.
-
Zydus Pharma Inc Recalls 9,504 Bottles of Risperidone Tablets
The ongoing Class III US nationwide including Puerto Rico voluntary recall is for Risperidone orally disintegrating tablets in the strength of 2 mg, United States Food and Drug Administration (USFDA) said in it's Enforcement Report for the week of March 2.
-
Zydus Gets US Regulator's Nod for Pain Reliever Tablets
Pharmaceuticals major Zydus Group on Wednesday announced receipt of approval from the US Food and Drug Administration (FDA) to sell chronic pain reliever morphine sulfate tablets.
-
Wockhardt, Cadila, Hospira Recall Drugs in US
Drug firms Wockhardt, Cadila Healthcare and Hospira are voluntarily recalling certain lots of drugs in the US, according to the US Food and Drug Administration (FDA).
-
Cadila, Zydus to settle patent infringement case with Depomed
Cadila Healthcare and Zydus Pharmaceuticals on Tuesday said they have entered into a settlement agreement with Depomed Inc pertaining to patent infringement.
-
Zydus Cadila's US Firm Gets US Approval To Market Roflumilast Tablets
Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of
-
Cadila Settles Patent Litigation Related To Anti-Seizure Drug
Drug firm Cadila Healthcare today said it has settled all outstanding patent litigation related to Qudexy XR (topiramate) extended-release capsules with US-based Upsher-Smith Laboratories, Inc.
-
Zydus To Sell Ulcerative Colitis Treatment Generic Drug In US Market
Drug firm Cadila Healthcare's US arm Zydus Pharmaceuticals (USA) Inc will start selling a generic version of Asacol HD, used for treatment of ulcerative colitis, in the American market from August 1, 2016.
-
Zydus Pharma Inc Recalls 9,504 Bottles of Risperidone Tablets
The ongoing Class III US nationwide including Puerto Rico voluntary recall is for Risperidone orally disintegrating tablets in the strength of 2 mg, United States Food and Drug Administration (USFDA) said in it's Enforcement Report for the week of March 2.
-
Zydus Gets US Regulator's Nod for Pain Reliever Tablets
Pharmaceuticals major Zydus Group on Wednesday announced receipt of approval from the US Food and Drug Administration (FDA) to sell chronic pain reliever morphine sulfate tablets.
-
Wockhardt, Cadila, Hospira Recall Drugs in US
Drug firms Wockhardt, Cadila Healthcare and Hospira are voluntarily recalling certain lots of drugs in the US, according to the US Food and Drug Administration (FDA).
-
Cadila, Zydus to settle patent infringement case with Depomed
Cadila Healthcare and Zydus Pharmaceuticals on Tuesday said they have entered into a settlement agreement with Depomed Inc pertaining to patent infringement.
